Paxil Related Published Studies
Well-designed clinical trials related to Paxil (Paroxetine)
Evidence Why Paroxetine Dose Escalation is Not Effective in Major Depressive Disorder: A Randomized Controlled Trial With Assessment of Serotonin Transporter Occupancy. [2008.10.01]
The effects of acute treatment with paroxetine, amitriptyline, and placebo on driving performance and cognitive function in healthy Japanese subjects: a double-blind crossover trial. [2008.07]
Luteal phase administration of paroxetine for the treatment of premenstrual dysphoric disorder: a randomized, double-blind, placebo-controlled trial in Canadian women. [2008.06]
Luteal Phase Administration of Paroxetine for the Treatment of Premenstrual Dysphoric Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial in Canadian Women. [2008.05.27]
Quetiapine augmentation of paroxetine CR for the treatment of refractory generalized anxiety disorder: preliminary findings. [2008.05]
Pharmacologic treatment of postpartum women with new-onset major depressive disorder: a randomized controlled trial with paroxetine. [2008.04]
Paroxetine CR augmentation for posttraumatic stress disorder refractory to prolonged exposure therapy. [2008.03]
Paroxetine with pindolol augmentation: A double-blind, randomized, placebo-controlled study in depressed in-patients. [2008.02]
Six-month paroxetine treatment of premenstrual dysphoric disorder: continuous versus intermittent treatment protocols. [2008.02]
Once-daily high-dose pindolol for paroxetine-refractory premature ejaculation: a double-blind, placebo-controlled and randomized study. [2008.02]
Effectiveness of paroxetine in the treatment of acute major depression in adults: a systematic re-examination of published and unpublished data from randomized trials. [2008.01.29]
Efficacy of paroxetine in treating major depressive disorder in persons with multiple sclerosis. [2008.01]
Paroxetine-induced modulation of cortical activity supporting language representations of action. [2008.01]
Paroxetine reduces social anxiety in individuals with a co-occurring alcohol use disorder. [2008]
Paroxetine versus placebo and other agents for depressive disorders: a systematic review and meta-analysis. [2007.12]
Pharmacological interaction between 3,4-methylenedioxymethamphetamine (ecstasy) and paroxetine: pharmacological effects and pharmacokinetics. [2007.12]
A randomized trial of paroxetine to prevent interferon-alpha-induced depression in patients with hepatitis C. [2007.11]
A randomized, single-blind, comparison of venlafaxine with paroxetine in elderly patients suffering from resistant depression. [2007.11]
Paroxetine oral solution is bioequivalent to paroxetine tablets--advantages of the solution. [2007.11]
A randomized controlled trial of venlafaxine ER and paroxetine in the treatment of outpatients with panic disorder. [2007.10]
Pharmacological Interaction Between 3,4-Methylenedioxymethamphetamine (MDMA, ecstasy) and Paroxetine: Pharmacological effects and pharmacokinetics. [2007.09.21]
Maintenance treatment for old-age depression preserves health-related quality of life: a randomized, controlled trial of paroxetine and interpersonal psychotherapy. [2007.09]
Clinical observation on treatment of depression by electro-acupuncture combined with Paroxetine. [2007.09]
Treatment with risperidone for 4 weeks increased plasma 3-methoxy-4-hydroxypnenylglycol (MHPG) levels, but did not alter plasma brain-derived neurotrophic factor (BDNF) levels in schizophrenic patients. [2007.06.30]
A randomized controlled trial of venlafaxine ER and paroxetine in the treatment of outpatients with panic disorder. [2007.06.23]
[Effects of paroxetine with or without zolpidem on depression with insomnia: a multi-center randomized comparative study] [2007.06.19]
Quality of life and metabolic status in mildly depressed patients with type 2 diabetes treated with paroxetine: a double-blind randomised placebo controlled 6-month trial. [2007.06.15]
Once-daily duloxetine 60 mg in the treatment of major depressive disorder: Multicenter, double-blind, randomized, paroxetine-controlled, non-inferiority trial in China, Korea, Taiwan and Brazil. [2007.06]
A randomized, controlled, trial of controlled release paroxetine in fibromyalgia. [2007.05]
Prediction of response to paroxetine and venlafaxine by serotonin-related genes in obsessive-compulsive disorder in a randomized, double-blind trial. [2007.05]
The MAOA T941G polymorphism and short-term treatment response to mirtazapine and paroxetine in major depression. [2007.04.05]
Escitalopram in obsessive-compulsive disorder: a randomized, placebo-controlled, paroxetine-referenced, fixed-dose, 24-week study. [2007.04]
A randomized trial of paroxetine to prevent interferon-alpha-induced depression in patients with hepatitis C. [2007.02.08]
Effect of itraconazole on pharmacokinetics of paroxetine: the role of gut transporters. [2007.02]
Cognitive behavior therapy and paroxetine in the treatment of hypochondriasis: a randomized controlled trial. [2007.01]
Placebo-controlled trial comparing intermittent and continuous paroxetine in premenstrual dysphoric disorder. [2007.01]
A validation of the 7.5% CO2 model of GAD using paroxetine and lorazepam in healthy volunteers. [2007.01]
Effects of three cytochrome P450 inhibitors, ketoconazole, fluconazole, and paroxetine, on the pharmacokinetics of lasofoxifene. [2007.01]
Terbinafine increases the plasma concentration of paroxetine after a single oral administration of paroxetine in healthy subjects. [2007.01]
Determination of paroxetine in plasma by liquid chromatography coupled to tandem mass spectrometry for pharmacokinetic and bioequivalence studies. [2007]
Differential antidepressant symptom efficacy: placebo-controlled comparisons of duloxetine and SSRIs (fluoxetine, paroxetine, escitalopram). [2007]
The MAOA T941G polymorphism and short-term treatment response to mirtazapine and paroxetine in major depression. [2006.12.27]
Improved insulin sensitivity in 80 nondiabetic patients with MDD after clinical remission in a double-blind, randomized trial of amitriptyline and paroxetine. [2006.12]
Comparison of Hypericum extract WS 5570 and paroxetine in ongoing treatment after recovery from an episode of moderate to severe depression: results from a randomized multicenter study. [2006.11]
Clinical application of paroxetine for tapering benzodiazepine use in non-major-depressive outpatients visiting an internal medicine clinic. [2006.10]
Paroxetine treatment improves motor symptoms in patients with multiple system atrophy. [2006.10]
Duloxetine in the treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. [2006.09]
Comparison of dapoxetine versus paroxetine in patients with premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomized study. [2006.09]
Paroxetine treatment of primary insomnia in older adults. [2006.09]
Alterations in stress reactivity after long-term treatment with paroxetine in women with posttraumatic stress disorder. [2006.07]
A comparative study of the efficacy of long-term treatment with escitalopram and paroxetine in severely depressed patients. [2006.07]
Comparison of venlafaxine extended release versus paroxetine for treatment of patients with generalized anxiety disorder. [2006.06]
Thyrotropin, but not a polymorphism in type II deiodinase, predicts response to paroxetine in major depression. [2006.06]
Paroxetine treatment in children and adolescents with major depressive disorder: a randomized, multicenter, double-blind, placebo-controlled trial. [2006.06]
Paroxetine: population pharmacokinetic analysis in late-life depression using sparse concentration sampling. [2006.05]
A double-blind, randomized, parallel-group, flexible-dose study to evaluate the tolerability, efficacy and effects of treatment discontinuation with escitalopram and paroxetine in patients with major depressive disorder. [2006.05]
A randomized double-blind trial of paroxetine and/or dextroamphetamine and problem-focused therapy for attention-deficit/hyperactivity disorder in adults. [2006.04]
Antiplatelet activity during coadministration of the selective serotonin reuptake inhibitor paroxetine and aspirin in male smokers: a randomized, placebo-controlled, double-blind trial. [2006.04]
Effects of paroxetine and venlafaxine on immune parameters in patients with obsessive compulsive disorder. [2006.04]
Sexual function during bupropion or paroxetine treatment of major depressive disorder. [2006.03]
A double-blind, multicenter, parallel-group study of paroxetine, desipramine, or placebo in breast cancer patients (stages I, II, III, and IV) with major depression. [2006.02]
An international, multicenter, placebo-controlled trial of paroxetine in adolescents with major depressive disorder. [2006.02]
Resolution of sexual dysfunction during double-blind treatment of major depression with reboxetine or paroxetine. [2006.01]
A randomized controlled trial of paroxetine for noncardiac chest pain. [2006.01]
Escitalopram versus paroxetine for social anxiety disorder: An analysis of efficacy for different symptom dimensions. [2006.01]
An open trial of paroxetine for the "offensive subtype" of taijin kyofusho and social anxiety disorder. [2006]
A randomized controlled trial of paroxetine for noncardiac chest pain. [2006]
Combined treatment with sulpiride and paroxetine for accelerated response in patients with major depressive disorder. [2005.12]
Effects of paroxetine on cardiovascular response to mental stress in subjects with a history of coronary artery disease and no psychiatric diagnoses. [2005.11]
Paroxetine is an effective treatment for hot flashes: results from a prospective randomized clinical trial. [2005.10.01]
Effects of paroxetine and venlafaxine XR on heart rate variability in depression. [2005.10]
Validation of a selective method for determination of paroxetine in human plasma by LC-MS/MS. [2005.08.17]
Chronic administration of selective serotonin reuptake inhibitor (SSRI) paroxetine modulates human motor cortex excitability in healthy subjects. [2005.08.15]
Luteal phase dosing with paroxetine controlled release (CR) in the treatment of premenstrual dysphoric disorder. [2005.08]
A comparative, randomised, double-blind study of trazodone prolonged-release and paroxetine in the treatment of patients with major depressive disorder. [2005.08]
Venlafaxine XR demonstrates higher rates of sustained remission compared to fluoxetine, paroxetine or placebo. [2005.07]
Sexual functioning assessed in 4 double-blind placebo- and paroxetine-controlled trials of duloxetine for major depressive disorder. [2005.06]
Short-term paroxetine treatment does not alter the motor response to levodopa in PD. [2005.05.24]
Controlled clinical comparison of paroxetine and fluvoxamine considering the serotonin transporter promoter polymorphism. [2005.05]
A double-blind comparison of escitalopram and paroxetine in the long-term treatment of generalized anxiety disorder. [2005.04]
Paroxetine, a cytochrome P450 2D6 inhibitor, diminishes the stereoselective O-demethylation and reduces the hypoalgesic effect of tramadol. [2005.04]
Do venlafaxine XR and paroxetine equally influence negative and positive affect? [2005.04]
Acute treatment of moderate to severe depression with hypericum extract WS 5570 (St John's wort): randomised controlled double blind non-inferiority trial versus paroxetine. [2005.03.05]
Comparison of fluoxetine and paroxetine in type II diabetes mellitus patients. [2005.03]
Efficacy screening trials of paroxetine, pentoxifylline, riluzole, pramipexole and venlafaxine in cocaine dependence. [2005.03]
Effect of paroxetine hydrochloride (Paxil) on fatigue and depression in breast cancer patients receiving chemotherapy. [2005.02]
Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder. [2005.02]
Incidence of sexual side effects in refractory depression during treatment with citalopram or paroxetine. [2005.01]
Selective serotonin reuptake inhibitor treatment for generalized anxiety disorder: a double-blind, prospective comparison between paroxetine and sertraline. [2005.01]
Efficacy and tolerability of controlled-release paroxetine in the treatment of panic disorder. [2005.01]
Negative symptoms of schizophrenia are improved by the addition of paroxetine to neuroleptics: a double-blind placebo-controlled study. [2005.01]
Contribution of cytochrome P450 2D6 to 3,4-methylenedioxymethamphetamine disposition in humans: use of paroxetine as a metabolic inhibitor probe. [2005]
Paroxetine Controlled Release for Premenstrual Dysphoric Disorder: Remission Analysis Following a Randomized, Double-Blind, Placebo-Controlled Trial. [2005]
Sleep laboratory study on single and repeated dose effects of paroxetine, alprazolam and their combination in healthy young volunteers. [2005]
Risperidone and paroxetine given singly and in combination for bipolar depression. [2004.12]
Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. [2004.12]
The effects of tianeptine or paroxetine on 35% CO2 provoked panic in panic disorder. [2004.12]
Triiodothyronine addition to paroxetine in the treatment of major depressive disorder. [2004.12]
A comparative study of milnacipran and paroxetine in outpatients with major depression. [2004.12]
Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression. [2004.11]
A multicenter, randomized, double-blind, placebo-controlled trial of paroxetine in children and adolescents with social anxiety disorder. [2004.11]
|
